V160 + MAPA

V160 + MAPA is a combination product used in clinical research settings. V160 refers to an investigational vaccine developed for the prevention of human cytomegalovirus (HCMV) infection. It is a recombinant subunit vaccine candidate designed to elicit immune responses against HCMV. MAPA in this context refers to an adjuvant or formulation component administered alongside V160 to enhance immunogenicity; however, the precise identity of "MAPA" as used here is not fully clarified in public sources and should not be confused with methyl alpha-phenylacetoacetate, which is a chemical precursor unrelated to vaccines[1][3]. The combination has been studied as an intramuscular injection for its safety and immunogenicity profile in healthy adults[1].